BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 14717619)

  • 1. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
    Christman AK; Fermo JD; Markowitz JS
    Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
    Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ
    Expert Opin Pharmacother; 2003 Jul; 4(7):1165-74. PubMed ID: 12831341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R; Castells X; Tobias A; Capellà D
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.